- Heldman, Madeleine R;
- Kates, Olivia S;
- Safa, Kassem;
- Kotton, Camille N;
- Georgia, Sarah J;
- Steinbrink, Julie M;
- Alexander, Barbara D;
- Hemmersbach‐Miller, Marion;
- Blumberg, Emily A;
- Multani, Ashrit;
- Haydel, Brandy;
- La Hoz, Ricardo M;
- Moni, Lisset;
- Condor, Yesabeli;
- Flores, Sandra;
- Munoz, Carlos G;
- Guitierrez, Juan;
- Diaz, Esther I;
- Diaz, Daniela;
- Vianna, Rodrigo;
- Guerra, Giselle;
- Loebe, Matthias;
- Rakita, Robert M;
- Malinis, Maricar;
- Azar, Marwan M;
- Hemmige, Vagish;
- McCort, Margaret E;
- Chaudhry, Zohra S;
- Singh, Pooja P;
- Kramer, Kailey Hughes;
- Velioglu, Arzu;
- Yabu, Julie M;
- Morillis, Jose A;
- Mehta, Sapna A;
- Tanna, Sajal D;
- Ison, Michael G;
- Derenge, Ariella C;
- Duin, David;
- Maximin, Adrienne;
- Gilbert, Carlene;
- Goldman, Jason D;
- Lease, Erika D;
- Fisher, Cynthia E;
- Limaye, Ajit P;
- Team, the UW COVID‐19 SOT Study
Mortality among patients hospitalized for COVID-19 has declined over the course of the pandemic. Mortality trends specifically in solid organ transplant recipients (SOTR) are unknown. Using data from a multicenter registry of SOTR hospitalized for COVID-19, we compared 28-day mortality between early 2020 (March 1, 2020-June 19, 2020) and late 2020 (June 20, 2020-December 31, 2020). Multivariable logistic regression was used to assess comorbidity-adjusted mortality. Time period of diagnosis was available for 1435/1616 (88.8%) SOTR and 971/1435 (67.7%) were hospitalized: 571/753 (75.8%) in early 2020 and 402/682 (58.9%) in late 2020 (p < .001). Crude 28-day mortality decreased between the early and late periods (112/571 [19.6%] vs. 55/402 [13.7%]) and remained lower in the late period even after adjusting for baseline comorbidities (aOR 0.67, 95% CI 0.46-0.98, p = .016). Between the early and late periods, the use of corticosteroids (≥6 mg dexamethasone/day) and remdesivir increased (62/571 [10.9%] vs. 243/402 [61.5%], p < .001 and 50/571 [8.8%] vs. 213/402 [52.2%], p < .001, respectively), and the use of hydroxychloroquine and IL-6/IL-6 receptor inhibitor decreased (329/571 [60.0%] vs. 4/492 [1.0%], p < .001 and 73/571 [12.8%] vs. 5/402 [1.2%], p < .001, respectively). Mortality among SOTR hospitalized for COVID-19 declined between early and late 2020, consistent with trends reported in the general population. The mechanism(s) underlying improved survival require further study.